0 154

Cited 0 times in

MARIPOSA-2: Randomized phase III study of amivantamab plus lazertinib plus chemotherapy vs chemotherapy alone in EGFRmutant NSCLC after osimertinib failure

Authors
 J. Wang  ;  R. Garcia Campelo  ;  N. Girard  ;  N. Leighl  ;  K. Reckamp  ;  T. Takahashi  ;  S. Li  ;  D. Millington  ;  P. Barala  ;  J.M. Bauml  ;  R.E. Knoblauch  ;  B.C. Cho 
Citation
 ANNALS OF ONCOLOGY, Vol.33(Suppl 9) : S1597, 2022-11 
Journal Title
ANNALS OF ONCOLOGY
ISSN
 0923-7534 
Issue Date
2022-11
Full Text
https://www.sciencedirect.com/science/article/pii/S0923753422046919
DOI
10.1016/j.annonc.2022.10.500
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/194594
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links